Upcoming events in English:
Webinar | Thursday June 12th 2025, 6PM UTC+3
Victoria Litman: The Necessity of Regulating Psychedelic Spiritual Care
(please note new date!)
Webinar | Tuesday June 17th 2025, 6PM UTC+3
Jules Evans: The Psychedelic Industry’s Entity Dilemma
(please note new date!)
• • • • •
Ketamine in Psychiatry – online seminar - Classic psychedelics may be making their way into psychiatric treatment in the next few years. But the psychedelic-like dissociative ketamine is already there. Join us on January 20, 2021 for a series of talks about the current and possible future roles of ketamine treatment in psychiatry. Read more
Psykedeelinäkymiä 2019: MDMA-assisted psychotherapy – why? - On Saturday, October 5th, 2019, the Finnish Association for Psychedelic Research will organize a full-day seminar titled “MDMA-assisted psychotherapy – why?” in Ruoholahti, Helsinki. The event is aimed at professionals and students of medicine, psychology, psychotherapy and other relevant fields, but is open to anyone interested in the topic. Read more
Psykedeelinäkymiä 2019 – Psychedelics and integration - In May, the spotlight will again be on psychedelics, as the Finnish Association for Psychedelic Research (Psykedeelitutkimusyhdistys ry, Psyty) organizes a lecture event in Helsinki on the theme of integrating psychedelic experiences. Psychologist and psychotherapist Marc Aixalà from Barcelona and psychologist Riikka Ajantaival will speak at the event. Read more
Psykedeelinäkymiä 2018 – MDMA and psilocybin assisted therapy - The Finnish Association for Psychedelic Research is organizing an all-day symposium on psychedelic research. The theme of the event is MDMA and psilocybin assisted therapy, featuring psychiatrist Ben Sessa, MD, from the UK, and Kim Kuypers, PhD, and Natasha Mason, MSc, from the Netherlands. Read more
Psykedeelinäkymiä 2017 – The therapeutic potential of psychedelics - The amount of scientific research on psychedelics has considerably increased during the last couple of decades. Substances like LSD, psilocybin, MDMA and ayahuasca are being studied as adjuncts to therapy for depression, addiction, post-traumatic stress disorder and anxiety related to terminal illness, and as tools for research on the neurobiology of consciousness. Two key experts… Read more